S -Methyl cysteine sulfoxide: its effects on cardiometabolic outcomes in high-fat fed C57BL/6 mice and relevance to human health

≤ 0.05). Other cardiometabolic parameters were not significantly altered. SMCSO did not improve glucose tolerance, mLDL-C, or blunt weight gain in high-fat fed mice. The higher SMCSO doses (170 and 350 mg per kg BW per day) lowered diet-induced elevations in HDL-C, although the mechanism is unclear. Whether this finding has relevance to human health remains unknown.